We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Binding Site Showcases Optilite System for Special Protein Testing

By LabMedica International staff writers
Posted on 22 May 2023
Print article
Image: Optilite special protein analyzer on display at EuroMedLab Rome 2023 (Photo courtesy of Binding Site)
Image: Optilite special protein analyzer on display at EuroMedLab Rome 2023 (Photo courtesy of Binding Site)

Binding Site (Birmingham, UK) is showcasing its Optilite system, the leading solution for multiple myeloma and immune status testing, at the 2023 EuroMedLab Congress.

Optilite represents a significant breakthrough in special protein testing. The innovative system has been fully optimized to simplify complex analytical processes, delivering unparalleled efficiency, workflow optimization, and confidence in test results. With an array of intelligent features, Optilite sets a new standard in the protein laboratory field by seamlessly integrating cutting-edge technology and advanced software.

At EuroMedLab Rome 2023, Binding Site is also presenting its range of in vitro assays, which have received the CE mark for Europe, FDA clearance for the USA, and approval from regulatory authorities in multiple countries. These comprehensive assays cover all five isotypes of immunoglobulins, offering a complete solution. Among the assays being highlighted by Binding Site at the industry event are Freelite and Hevylite, which provide a comprehensive monitoring solution for managing patients with multiple myeloma.

The Freelite assay has significantly enhanced laboratory and clinical practices in the detection and follow-up of monoclonal gammopathies. The Optilite Freelite assay, FDA-cleared for aiding in the diagnosis and monitoring of multiple myeloma, represents the state-of-the-art in free light chain testing. Additionally, Hevylite is a unique immunoassay panel designed to accurately identify and quantify immunoglobulin heavy and light chain isotypes. Together, these advancements by Binding Site contribute to the advancement of diagnostic and monitoring capabilities in the field of multiple myeloma.

Related Links:
Binding Site 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more